11丁苯酞的药理作用与临床评价08.9.15

izedamphotericinBdesoxycholateandliposomalamphotericinBinthetreatmentofinvasivepulmonaryaspergillosisinse2verelyimmunocompromisedrats[J].JAntimicrobChemother,2001,48(1):89295.[6]JoshiMR,MisraA.Liposomalbudesonidefordrypowderin2haler:preparationandstabilization[J].AAPSPharmSciTech,2001,2(4):25.[7]JoshiM,MisraA.Pulmonarydispositionofbudesonidefromliposomaldrypowderinhaler[J].MethodsFindExpClinPhar2macol.,2001,23(10):5312536.[8]KonduriKS,NandedkarS,DzgnesN,etal.Efficacyofli2posomalbudesonideinexperimentalasthma[J].JAllergyClinImmunol,2003,111(2):3212327.[9]KoshkinaNV,WaldrepJC,RobertsLE,etal.Paclitaxellipo2someaerosoltreatmentinducesinhibitionofpulmonarymetas2tasesinmurinerenalcarcinomamodel[J].ClinCancerRes,2001,7(10):325823262.[10]VerschraegenCF,GilbertBE,LoyerE,etal.Clinicalevalua2tionofthedeliveryandsafetyofaerosolizedliposomal92nitro220(s)2camptothecininpatientswithadvancedpulmonaryma2lignancies[J].ClinCancerRes,2004,10(7):231922326.[11]HuangYY,WangCH.Pulmonarydeliveryofinsulinbylipo2somalcarriers[J].JControlRelease,2006,113(1):9214.[12],.[J].,2002,37(5):3782382.[13]LuD,HickeyAJ.Liposomaldrypowdersasaerosolsforpul2monarydeliveryofproteins[J].AAPSPharmSciTech,2005,6(4):E6412648.[14]ZouY,ZongG,LingYH,etal.Developmentofcationiclipo2someformulationsforintratrachealgenetherapyofearlylungcancer[J].CancerGeneTher,2000,7(5):6832696.[15]SevillePC,KellawayIW,BirchallJC.Preparationofdrypow2derdispersionsfornon2viralgenedeliverybyfreeze2dryingandspray2drying[J].JGeneMed,2002,4(4):4282437.[16],.[J].,2004,26(5):3522356.[17]ArndtD,ZeisigR,BechtelD,etal.Liposomalbleomycin:in2creasedtherapeuticactivityanddecreasedpulmonarytoxicityinmice[J].DrugDeliv,2001,8(1):127.[18]DokkaS,ToledoD,ShiX,etal.Oxygenradical2mediatedpulmonarytoxicityinducedbysomecationicliposomes[J].PharmRes,2000,17(5):5212525.[]2007210214[],,,,:139704861681,1,1,2(1.,344000;2.,550001)[]::,5::,()[];;[]R969[]A[]100125213(2008)1721498203,:,:butylphthalidesoftcapsules,232(NBP):C12H14O2,:190.24,,15,861,NOPGI2,,,,,;,;,;,;,,22.12.1.1240mgkg-1,1h25.44mg,42%,5h4.88mg,8.1%,2.1.2,III22.1.370%3H224h55.2%,2.7%;18.5%,0.9%;48h,0.022%894120082817ChinHospPharmJ,2008Sep,Vol28,No.172.2100,200,400mg,0.88,1.25,1.25h;(78.7115.8),(204.7149.0),(726.6578.7)gL-1;(12.52.5),(11.84.1),(7.51.3)h;AUC02t(93.2114.0),(323.8201.0),(1314.2965.7)gL-1h200mg,1h4h;204.7gL-167.0gL-1;AUC02tAUC02323.8gL-1h460.5gL-1h136.8gL-1h193.6gL-1h200mg,tmaxCmaxAUC02(P0.05),,200mg,qid,13,(1.00.5),(1.20.8),3IIIIIIV12GCP()IV,,11()94,(WHO)NIHSSBarthel,2050,78.2%,94%,,,NOPGI2,,,,,,,[1]3.1,,Calci2neurinCalpain,,[2],52,[3];,,[4]NMDA[5],,,[627]3.2,,cAmP52,[8]3.3,,,,[9]3.4[10],,[11](TIA),,,,,,TIA[12],,,[13],,4,5,,,IIIII,:(ALT)(39643);(AST)(39630);()(3961);(3964)231112;2;BUN1;3114964;3;BUN2;BUNCr1;1;1IV,2000,,,IIIII;,()(),6,110/10,60%80%,,,,1h,,;,3:,;,;,,,994120082817ChinHospPharmJ,2008Sep,Vol28,No.17:[1],,,.J].,2005,2(3):1122115.[2],.[J].,2000,35(10):7902792.[3],.52[J].,1999,34(9):591.[4],.[J].,1999,34(12):8932897.[5],,.KClN22D2[J].,1997,32(8):340.[6],,.[J].,1995,30(6):741.[7]WeissJ,ColdbergMp,ChoiDW.Ketamineprotectsculturedneocorticalneuronsfromhypoxicinjury[J].BrainRes,1986,380:186.[8],.[J].,2001,36(5):3292333.[9],,,.[J].,2005,14(8):9852988.[10],,,.[J].,2006,25(7):5082511.[11],,,.[J].,2007,26(9):6682671.[12].dl232[J].,2007,5(5):4662467.[13],.[J].,1996,31(5):13.[]2008203210[],,,,:010264012266a,b(,a.,b.,100700)[];;[]R977.3[]A[]100125213(2008)1721500202(enteralnutrition,EN),Wilmore,[1],,,12:1.1,,,:(1),;(2),1.2,(300450mOsmL-1),,,:(1);,(fresubin)(nutrisonfibre);,(ensure)(elental)(2)::(fresubindiabetes);:(supportan);,(impact);,(pulmocare);,(fresubin750MCT,)(3):,2,,:(1);(2);(3);(4);(5);(6);(7);(8);(9),,,,3,,344.1,,,EN[2],,24h,005120082817ChinHospPharmJ,2008Sep,Vol28,No.17